Latest Prothrombin time Stories
RIDGEFIELD, Conn., Feb.
Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.
PARSIPPANY, N.J., Dec.
INDIANAPOLIS, July 26 /PRNewswire/ -- Roche Diagnostics announced today it has received 510(k) clearance from the U.S.
In the news release, FDA grants CLIA-waived status to CoaguChek XS Plus system for PT/INR testing at the point of care, issued yesterday by Roche Diagnostics, Inc.
INDIANAPOLIS, March 30 /PRNewswire/ -- Roche Diagnostics announced today that the U.S.
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.
NEW ORLEANS, Dec. 6 /PRNewswire-USNewswire/ -- Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured.
BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than patients given edoxaban twice a day (BID).
Researchers from Boston University School of Medicine (BUSM) have determined the optimal dose-management strategy to derive maximal benefit from warfarin therapy and improve patient outcomes.